Skip to main content
. 2022 Feb 1;10(2):346. doi: 10.3390/biomedicines10020346

Figure 3.

Figure 3

Proposed therapeutic applications of hMOS in COVID-19. (a) Aerosolized inhalation for prevention and/or treatment. (b) Intravenous administration for systemic anti-inflammation and immunomodulation. (c) Oral administration for prebiotic effects to restore gut dysbiosis which may mitigate chronic inflammation and neurological symptoms via gut-brain axis in long-COVID through (d) systemic absorption of ingested hMOS.